GDM Diagnostic Development Services

GDM Diagnostic Development Services

Gestational diabetes mellitus (GDM) is a common condition that poses risks to the mother and offspring. Diagnosis of diabetes can help researchers efficiently analyze the causes of diabetes and advance the development of therapies. Ace Therapeutics can provide diagnostic development service of GDM with more efficient function analysis.

Overview of GDM Diagnosis

Gestational diabetes mellitus (GDM) develops in pregnant people whose pancreatic function is insufficient to overcome the insulin resistance. The goal of screening and diagnostic is to reduce maternal and fetal complications. The association between adverse pregnancy outcomes and maternal glycaemia is a continuum, so current diagnostic criteria are based on consensus rather than definitive demarcation of risk.

Fig 2. Effects of Diabetes on Lipoprotein MetabolismEffects of Diabetes on Lipoprotein Metabolism (Robert, H. E.; et al. Cell Metabolism. 2021)

GDM Diagnostic Markers

Routine plasma glucose, insulin, C-peptide, homeostatic model assessment of insulin resistance, and sex hormone-binding globulin can differentiate between healthy pregnant women and those with GDM. Consensus criteria for the diagnosis markers of GDM are based on an increased risk of fetal weight, fetal adiposity (body fat percentage), and cord blood C-peptide, reflecting increased fetal insulin production in response to maternal hyperglycemia.

  • Glucose-related Biomarkers
    The blood-based glucose-related testing includes hemoglobin Ale (HbAlc) (a product of non-enzymatic glycation), the fasting plasma glucose (FPG), and oral glucose tolerance test (OGTT).
  • C-peptide Level
    Stimulated serum C-peptide level (as a surrogate for insulin) has been considered a consistent and sensitive measure of β-cell function and can be used to help diagnosed with gestational diabetes mellitus.
  • Potential Biomarkers
    In addition to the hormones that fluctuate during pregnancy, as well as adipokine and inflammatory, there are other biomarkers that can be used in the diagnosis of GDM. Proteins, nucleic acids, and metabolites, et al., that can be detected by metabolomic techniques.

Fig 3. Obesity-Induced Inflammation and Insulin Resistance Obesity-Induced Inflammation and Insulin Resistance (Jerrold, M. O. Cell. 2009)

Methods for GDM Diagnosis

Screening and diagnosis for gestational diabetes in asymptomatic persons involves either a 2-step (screening test followed by a diagnostic test) or 1-step (diagnostic test used for all patients) approach. In addition, the blood samples can employ metabolomic techniques, such as 1D 1H NMR and mass spectroscopy (FIA-MS/MS and LC-MS/MS) to identify novel markers.

Fig 4. Adipose Tissue Expansion Promotes Insulin ResistanceAdipose Tissue Expansion Promotes Insulin Resistance (Isabelle, C.; et al. Trends in Endocrinology & Metabolism. 2012)

Our Services

Effective diagnostics can help clients complete their disease model analysis more efficiently and help accelerate therapy development of gestational diabetes mellitus. Ace Therapeutics can provide the GDM diagnostic development services for different diagnostic markers (glucose, HbAlc, C-peptide, anti-insulin hormones, adipokine and inflammatory, proteins, nucleic acids, and metabolites, et al.).

In addition, we provide GDM biomarker development and GDM therapy development service for our clients worldwide.

Features of Our Services

Highly CustomizableHighly Customizable

One-stop ServicesOne-stop Services

High QualitysHigh Quality

Professional TeamProfessional Team

Ace Therapeutics offers cost-effect and high-quality research services related to gestational diabetes mellitus diagnostic development for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.


  1. Bentley, R.; et al. Gestational diabetes mellitus: postpartum opportunities for the diagnosis and prevention of type 2 diabetes mellitus. Nature Clinical Practice Endocrinology & Metabolism. 2008, 4.10, 552-558.
  2. Naeh A, Maor-Sagie E, Hallak M, Gabbay-Benziv R. Early Identification of the Maternal, Placental and Fetal Dialog in Gestational Diabetes and Its Prevention. Reproductive Medicine. 2022; 3(1):1-14.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
Contact Info
Copyright © Ace Therapeutics. All Rights Reserved.